Mechanism of the Cardiotoxic Actions of Terfenadine
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVES AND METHODS: To gain insight into possible mechanisms of and predisposing factors for torsades de pointes during terfenadine therapy, spontaneous reports in the US Food and Drug Administration's Spontaneous Reporting System database were examined. Based on the characteristics of the cases, in vitro cardiac electrophysiologic studies were conducted to test the hypothesis that terfenadine, and not its major metabolite, has actions similar to those of quinidine and is responsible for this form of cardiac toxicity. DESIGN: Spontaneous reports from the general medical community. RESULTS: As of April 1, 1992, 25 cases of torsades de pointes had been reported to the Food and Drug Administration's Spontaneous Reporting System. Predisposing factors in these cases indicated that the parent drug, but not its metabolite, may have actions similar those of quinidine that are responsible for inducing arrhythmia. In vitro studies found that terfenadine is equipotent to quinidine as a blocker of the delayed rectifier potassium current in isolated feline myocytes. The metabolite, terfenadine carboxylate, did not inhibit this potassium current even at concentrations 30 times higher than the concentration of terfenadine producing a half-maximal effect. CONCLUSIONS: Since blockade of the potassium channel did not occur with the major metabolite of terfenadine, episodes of torsades de pointes are most likely the result of a quinidinelike action of the parent drug and of factors that impair the normally rapid metabolism of terfenadine. Dosage restriction and awareness of the clinical conditions and drug interactions capable of inhibiting the metabolism of terfenadine are essential for prevention of this serious reaction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, adverse cardiac effects (torsades de pointes, arrhythmia, and prolongation of the QT interval) were reported with astemizole and terfenadine, leading to their ultimate withdrawal from the market.1168,1169”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1168]
In the citing paper
“Cerivastatin (Section 7.7) and terfenadine (Section 7.9) are metabolism- and interaction-dependent failures, in which a cytochrome P450 drug interaction rather than body size dictated the clinically decisive exposure.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [83]
In the citing paper
“Reports of torsades de pointes and sudden death emerged when terfenadine was co-administered with CYP3A4 inhibitors such as ketoconazole, erythromycin, and the constituents of grapefruit juice, conditions under which parent terfenadine accumulated to concentrations sufficient to prolong QTc and trigger ventricular arrhythmia [82,83].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [83]
In the citing paper
“Body-weight allometric scaling applied to total drug exposure would not have flagged a problem, because in monotherapy, preclinical species and humans both metabolize terfenadine efficiently, and parent plasma concentrations remain low.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [83]
In the citing paper
“(ii) the inversion of the parent-to-metabolite exposure ratio under CYP3A4 inhibition, converting a notionally safe prodrug system into a hERG-blockade liability;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [83]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
Jackman, W. M., Friday, K. J., Anderson, J. L., Aliot, E. M., Clark, M., & Lazzara, R. (1988) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(88)90014-x · Cited by 783
Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current.
January, C. T., & Riddle, J. M. (1989) · Circulation Research · doi:10.1161/01.res.64.5.977 · Cited by 673
Torsades de Pointes Occurring in Association With Terfenadine Use
Monahan, B. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210088038 · Cited by 667
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Roden, D. M., Woosley, R. L., & Primm, R. K. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90010-4 · Cited by 488
Self-citationHonig, P. K., Woosley, R. L., Zamani, K., Conner, D. P., & Cantilena, L. R. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.135 · Cited by 367
Self-citationPeter, F., & Kim, D.-H. (1990) · Carcinogenesis · doi:10.1093/carcin/11.12.2275 · Cited by 245
Goldberg, R. J., Bengtson, J., Chen, Z., Anderson, K. M., Locati, E., & Levy, D. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90099-7 · Cited by 231
Follmer, C. H., & Colatsky, T. J. (1990) · Circulation · doi:10.1161/01.cir.82.1.289 · Cited by 178
Terfenadine A Review of its Pharmacodynamic Properties and Therapeutic Efficacy
Sorkin, E. M., & Heel, R. C. (1985) · Drugs · doi:10.2165/00003495-198529010-00002 · Cited by 172
Cited by
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs
Makkar, R. R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510210076031 · Cited by 971
Drug induced QT prolongation and torsades de pointes
Yap, Y. G., & Camm, A. J. (2003) · Heart · doi:10.1136/heart.89.11.1363 · Cited by 958
“Since 1986, certain non-sedating antihistamines, the so called second generation antihistamines (mainly terfenadine and astemizole), have been reported to cause QT prolongation and, in some cases, TdP.”
Background
Metadata
- Authors
- Woosley, R. L.
- Affiliations
- Georgetown University Medical Center (US)
- Corresponding author
- Woosley, Raymond L.
- ORCID
- Woosley, Raymond L.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1993-03-24
- Volume
- 269
- Issue
- 12
- Pages
- 1532
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2052085254
- Cited by
- 646
- References
- 26
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 2 · 2023: 10 · 2022: 5 · 2021: 14 · 2020: 9 · 2019: 10 · 2018: 7 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 20 · 2013: 17 · 2012: 16
- FWCI
- 33.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- terfenadine, torsades de pointes, cardiotoxicity, delayed rectifier potassium current, drug metabolites, drug interactions, drug metabolism inhibition, cardiac arrhythmias, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Aged, Animals, Cats, Dose-Response Relationship, Drug, Female, Heart, Humans, Male, Middle Aged, Myocardium, Quinidine, Vectorcardiography, Potassium Channels, Torsades de Pointes, Terfenadine, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanism of the Cardiotoxic Actions of Terfenadine. https://app.cochat.ai/papers/10.1001/jama.1993.03500120070028
- The paper
- Woosley, R. L. (1993). Mechanism of the Cardiotoxic Actions of Terfenadine. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1993.03500120070028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.